RETA Reata Pharmaceuticals Inc

Price (delayed)

$109.94

Market cap

$4B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.7

Enterprise value

$3.24B

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. ...

Highlights
Reata Pharmaceuticals's EPS has increased by 29% YoY
The net income has grown by 21% YoY
The company's equity rose by 35% YoY but it fell by 15% QoQ
RETA's quick ratio has shrunk by 52% YoY and by 8% QoQ
Reata Pharmaceuticals's gross profit has decreased by 49% YoY and by 10% QoQ

Key stats

What are the main financial stats of RETA
Market
Shares outstanding
36.39M
Market cap
$4B
Enterprise value
$3.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.71
Price to sales (P/S)
514.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
418.24
Earnings
Revenue
$7.76M
EBIT
-$223.41M
EBITDA
-$222.27M
Free cash flow
-$156.85M
Per share
EPS
-$7.7
Free cash flow per share
-$4.32
Book value per share
$8.65
Revenue per share
$0.21
TBVPS
$21.42
Balance sheet
Total assets
$777.61M
Total liabilities
$463.78M
Debt
$0
Equity
$313.83M
Working capital
$646.58M
Liquidity
Debt to equity
0
Current ratio
6.34
Quick ratio
6.24
Net debt/EBITDA
3.4
Margins
EBITDA margin
-2,865.1%
Gross margin
100%
Net margin
-3,498.2%
Operating margin
-2,879.7%
Efficiency
Return on assets
-35.4%
Return on equity
-84.4%
Return on invested capital
N/A
Return on capital employed
-34%
Return on sales
-2,879.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RETA stock price

How has the Reata Pharmaceuticals stock price performed over time
Intraday
2.2%
1 week
1.39%
1 month
-0.37%
1 year
6.37%
YTD
-11.07%
QTD
-22.32%

Financial performance

How have Reata Pharmaceuticals's revenue and profit performed over time
Revenue
$7.76M
Gross profit
$7.76M
Operating income
-$223.41M
Net income
-$271.39M
Gross margin
100%
Net margin
-3,498.2%
Reata Pharmaceuticals's net margin has plunged by 56% YoY and by 13% from the previous quarter
Reata Pharmaceuticals's gross profit has decreased by 49% YoY and by 10% QoQ
Reata Pharmaceuticals's revenue has decreased by 49% YoY and by 10% from the previous quarter
The operating income is up by 34% YoY but it is down by 4.5% from the previous quarter

Growth

What is Reata Pharmaceuticals's growth rate over time

Valuation

What is Reata Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.71
P/S
514.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
418.24
Reata Pharmaceuticals's EPS has increased by 29% YoY
The company's equity rose by 35% YoY but it fell by 15% QoQ
The stock's price to book (P/B) is 5% less than its last 4 quarters average of 13.4
Reata Pharmaceuticals's revenue has decreased by 49% YoY and by 10% from the previous quarter
The P/S is 7% above the last 4 quarters average of 482.5

Efficiency

How efficient is Reata Pharmaceuticals business performance
The ROE has soared by 60% YoY and by 4.5% QoQ
RETA's return on assets is up by 42% year-on-year and by 2.5% since the previous quarter
Reata Pharmaceuticals's ROS has decreased by 30% YoY and by 16% from the previous quarter

Dividends

What is RETA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RETA.

Financial health

How did Reata Pharmaceuticals financials performed over time
RETA's total assets is 68% more than its total liabilities
The current ratio has dropped by 53% year-on-year and by 10% since the previous quarter
RETA's quick ratio has shrunk by 52% YoY and by 8% QoQ
Reata Pharmaceuticals's debt is 100% less than its equity
The company's equity rose by 35% YoY but it fell by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.